It is currently Tue Feb 07, 2012 5:24 pm

Debio 0932 (formerly CUDC-305) is a small molecule inhibitor of Heat Shock Protein 90 (Hsp90). Debio0932 is expected to enter Phase I clinical testing in early Q1 2010.

News of HSP90 Debio-0932 (CUDC-305) » Site map of HSP90 Debio-0932 (CUDC-305)

About Debio-0932 (CUDC-305)
on Thu Feb 11, 2010 5:12 pm
CUDC-305 / Debio HSP90 overcomes erlotinib resistance
on Thu Feb 11, 2010 5:16 pm

Last 15 active topics

Hedgehog Pathway Cancers Clinical Trials

Hedgehog Pathway Articles

CU-907 (Inhibitor HDAC and PI3K/mTOR)

About CUDC-907

CU-906 (Inhibitor HDAC and PI3K/mTOR)

CU-906 Preclinical information

CU-201 (an Inhibitor of HDAC, SFK and Abl Kinases)

CU-201 Preclinical Data

Hedgehog Pathway Clinical Implications

Resistance to hedgehog pathway SMO Inhibitors

Statistics

Total posts 46 • Total topics 32 • Total members 44

GYM sitemaps & RSS

Curis Hedgehog and Beyond --plus multi-targeting cancer inhibitors

Site map of HSP90 Debio-0932 (CUDC-305)

News of HSP90 Debio-0932 (CUDC-305) » Forum : HSP90 Debio-0932 (CUDC-305)

Last 15 active topics

Login • Register

Statistics